Indefinite Delivery Contract HHSN261201500036I
Award Date
9/22/15
Last Date to Order
9/21/18
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The $149,995,000 multiple-award IDIQ contract supports the NCI's "PREVENT Cancer Preclinical Drug Development Program" and covers preclinical efficacy and biomarker evaluation of potential cancer preventive agents. Under this IDC, MD Anderson has been awarded a $1,144,300...
The federal contract IDV award was issued by the National Cancer Institute (NCI) for "Preclinical In Vitro and In Vivo Agent Development Assays" with a ceiling value of $0. The multiple-award IDC has a parent master IDIQ contract titled "Preclinical Agent Development Assays 2012-2016" and was awarded to the University of Alabama at Birmingham (UAB) on September 20, 2012, with an ultimate completion date of September 19, 2014. Under this IDC, UAB has been issued several...
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award IDC, valued at up to $149,995,000, aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $19,000,000 multiple-award IDC, designated as the "PREVENT Toxicology and Pharmacology Testing (PREVENT TOX)" program, aims to provide a structured approach to the development of cancer drugs and vaccines from...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, was awarded an Indefinite Delivery Contract (IDC) valued at $149,995,000 from the National Cancer Institute (NCI) to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award contract aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract is divided into three separate pools: evaluating...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...